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ORIGINAL ARTICLE

Clinical and Laboratory Features Distinguishing
Juvenile Polymyositis and Muscular Dystrophy
GULNARA MAMYROVA,1 JAMES D. KATZ,1 ROBERT V. JONES,1 IRA N. TARGOFF,2
PETER A. LACHENBRUCH,3 OLCAY Y. JONES,1 FREDERICK W. MILLER,3 LISA G. RIDER,3
CHILDHOOD MYOSITIS HETEROGENEITY COLLABORATIVE STUDY GROUP

AND THE

Objective. To differentiate juvenile polymyositis (PM) and muscular dystrophy, both of which may present with chronic
muscle weakness and inﬂammation.
Methods. We studied 39 patients with probable or deﬁnite juvenile PM and 9 patients with muscular dystrophies who
were initially misdiagnosed as having juvenile PM. Differences in demographic, clinical, and laboratory results; outcomes; and treatment responses were evaluated by Fisher’s exact and rank sum tests. Random forests classiﬁcation
analysis and logistic regression were performed to examine signiﬁcant differences in multivariable models.
Results. Clinical features and serum muscle enzyme levels were similar between juvenile PM and dystrophy patients,
except 89% of dystrophy patients had muscle atrophy compared with 46% of juvenile PM patients. Dystrophy patients
had a longer delay to diagnosis (median 12 versus 4 months) and were less frequently hospitalized than juvenile PM
patients (22% versus 74%). No dystrophy patients, but 54% of juvenile PM patients, had a myositis autoantibody.
Dystrophy patients more frequently had myopathic features on muscle biopsy, including diffuse variation of myoﬁber
size, ﬁber hypertrophy, and myoﬁber ﬁbrosis (44 –100% versus 8 –53%). Juvenile PM patients more frequently had
complex repetitive discharges on electromyography and a complete response to treatment with prednisone or other
immunosuppressive agents than dystrophy patients (44% versus 0%). Random forests analysis revealed that the most
important features in distinguishing juvenile PM from dystrophies were myositis autoantibodies, clinical muscle atrophy,
and myoﬁber size variation on biopsy. Logistic regression conﬁrmed muscle atrophy, myoﬁber ﬁbrosis, and hospitalization as signiﬁcant predictors.
Conclusion. Muscular dystrophy can present similarly to juvenile PM. Selected clinical and laboratory features are
helpful in combination in distinguishing these conditions.

INTRODUCTION
The juvenile idiopathic inﬂammatory myopathies (IIMs)
are a rare group of systemic autoimmune disorders characterized by chronic skeletal muscle inﬂammation of unknown causes, with onset at age ⬍18 years (1). Although
juvenile dermatomyositis is the primary clinical subgroup
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of juvenile IIMs, juvenile polymyositis (PM) has a prevalence of 2– 8% of all juvenile IIMs (2,3). Juvenile PM can
be more difﬁcult to diagnose because it lacks the characteristic cutaneous manifestations of juvenile dermatomyositis and has a different distribution of muscle weakness
and myopathologic features (4,5).
Some forms of muscular dystrophies in children can
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Signiﬁcance & Innovations
●

Muscular dystrophy can present similarly to juvenile polymyositis (PM).

●

Certain clinical and laboratory features can be
helpful in distinguishing juvenile PM and muscular dystrophy, including myositis autoantibodies,
as well as less frequent clinical muscle atrophy
and myoﬁber size variation on muscle biopsy.

mimic juvenile PM. However, juvenile PM and dystrophies have different biopsy characteristics, including immunopathologic features, but share some common clinical
manifestations (6). The histopathologic hallmark of juvenile PM is the presence of endomysial lymphocytic inﬁltration, but muscle inﬂammation has been reported
in some dystrophies, including Duchenne’s muscular dystrophy, facioscapulohumeral muscular dystrophy, limbgirdle muscular dystrophy type 2B, and congenital muscular dystrophy with primary merosin deﬁciency (4,6).
Several patients were referred to our studies and clinics
as having juvenile PM. However, upon detailed examination of their clinical features and review of their muscle
biopsy specimens, followed by immunohistochemical or
genetic testing, they were determined to have muscular
dystrophies. We systematically examined demographic,

clinical, and laboratory results; outcomes; and responses
to therapy of patients with juvenile PM and those misdiagnosed with muscular dystrophy to better understand the
distinguishing characteristics of these diseases.

PATIENTS AND METHODS
Patients. Thirty-nine patients with probable or deﬁnite
juvenile PM by the Bohan and Peter criteria, deﬁned as
the absence of characteristic skin rashes of dermatomyositis, including Gottron’s papules and heliotrope
rash (7,8), and 9 patients with muscular dystrophies eventually diagnosed by standard clinical/genetic criteria
(9,10) were included. Patients were enrolled in Institutional Review Board–approved natural history protocols
at the National Institutes of Health Clinical Center, Food
and Drug Administration, or George Washington University. The research was performed in accordance with the
ethical standards of the Declaration of Helsinki. Patients
with juvenile PM were diagnosed between 1987 and 2006
and patients with muscular dystrophy were diagnosed
between 1994 and 2009; all were diagnosed before age 18
years. A standardized questionnaire that included demographic, clinical, and laboratory test results (including
electromyography [EMG], magnetic resonance imaging
[MRI], and muscle biopsy data); treatment responses; and
outcome information was completed by each patient’s

Table 1. Demographic and outcome features of patients with juvenile PM
versus muscular dystrophy*

Age at diagnosis, median (IQR) years
Age at onset, median (IQR) years
Delay in diagnosis, median (IQR) months
Female sex
Race
White
Nonwhite
Illness onset speed
Insidious (⬎6 months)
Slow (3–6 months)
Subacute (1–3 months)
Acute (⬍1.0 month)
Disease severity at onset
Mild or moderate
Severe or very severe
Family history of autoimmune disease
Outcome features
Hospitalization
Wheelchair use
Death

Juvenile PM
(n ⴝ 39)

Dystrophy
(n ⴝ 9)

12.0 (1.7–18.0)
11.7 (2.0–16.9)
4.0 (1.0–108.0)†
30 (76.9)

9.1 (4.4–16.9)
9.0 (3.0–16.8)
12.0 (0.0–72.0)†
5 (55.6)

19 (48.7)
20 (51.3)

7 (77.8)
2 (22.2)

15 (38.5)
11 (28.2)
9 (23.1)
4 (10.3)

7 (77.8)
1 (11.1)
0 (0.0)
1 (11.1)

18 (46.2)
21 (53.8)
21 (55.3)

6 (66.7)
3 (33.3)
2 (22.2)

28 (73.7)‡
8 (20.5)
4 (10.5)

2 (22.2)‡
2 (22.2)
0 (0.0)

* Values are the number (percentage) unless indicated otherwise. Percentages may not reﬂect the number
divided by the total number of subjects when data are missing. PM ⫽ polymyositis; IQR ⫽ interquartile
range.
† P ⫽ 0.01.
‡ P ⫽ 0.007.

Features Distinguishing Juvenile Polymyositis and Dystrophies
treating physician, with details of the questionnaire and its
deﬁnitions explained previously (2,11). Progression of the
ﬁrst symptoms of illness to full disease presentation was
characterized as acute if it occurred in ⬍1 month, subacute
if it occurred in 1–3 months, slow if it occurred over 3– 6
months, and insidious if the time to full illness presentation was ⬎6 months. Severity of illness at onset, up to the
time of diagnosis, was determined by the enrolling physician and was graded on a 4-point Likert scale from mild to
extremely severe disease activity. Family history of autoimmune disease was recorded for ﬁrst- and second-degree
relatives. Muscle enzyme values were adjusted to a common upper limit of normal, with the highest value recorded. Mortality status was established using the Social
Security Death Index, which was last examined in March
2011 (2). Responses to therapy were categorized as complete clinical response if there was no remaining disease
activity after an adequate treatment trial, as deﬁned in the
study by Joffe et al (12), partial clinical response if there
was improvement but not remission, and no clinical response if there was no clinical improvement despite an
adequate treatment trial (12).
Thirty-one patients were diagnosed with juvenile PM
only and 8 patients were classiﬁed as having juvenile PM
overlapping with a second autoimmune disease; the majority of patients have been previously reported (2). Among
the 8 patients with overlap myositis, 4 had juvenile PM
overlapping with systemic lupus erythematosus, and 1
each had juvenile PM overlapping with ulcerative colitis,
Sjögren’s syndrome, eosinophilic fasciitis, and juvenile
idiopathic arthritis in combination with Sjögren’s syndrome. All juvenile IIM patients had a muscle biopsy
sample consistent with an inﬂammatory myopathy; the
majority of biopsy specimens were reviewed by 2 myositis
researchers (LGR, FWM), often with pathologists from
the Department of Neuropathology of the Armed Forces
Institute of Pathology, Washington, DC, or by a muscle
pathologist from the Department of Pathology at George
Washington University (RVJ).
All patients with muscular dystrophies were initially
enrolled by the treating physician as having juvenile PM,
and their diagnosis was revised after review of their questionnaire data and muscle biopsy sample, followed by
specialized immunohistochemical and/or genetic testing
to conﬁrm the speciﬁc diagnosis. Through genetic testing
and/or immunohistochemical staining of the muscle biopsy specimen, 1 patient was found to have Duchenne’s
muscular dystrophy, 1 was a carrier for Duchenne’s muscular dystrophy, 2 had facioscapulohumeral muscular
dystrophy, 2 had Emery-Dreifuss dystrophy, 1 had dysferlin dystrophy, 1 had calpain deﬁciency, and 1 had limbgirdle dystrophy. Sera were tested for myositis-speciﬁc
autoantibodies and myositis-associated autoantibodies by
using validated immunoprecipitation and immunoblotting
methods (13,14).
Statistical analysis. GraphPad Instat for Windows,
version 3.06 (www.graphpad.com) was used for basic statistical analyses. Summary data were expressed as medi-
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Table 2. Clinical features of patients with juvenile PM
versus muscular dystrophy*
Juvenile PM Dystrophy
(n ⴝ 39)
(n ⴝ 9)
Musculoskeletal system
Proximal muscle weakness
Distal muscle weakness
Myalgias
Falling
Muscle atrophy
Asymmetric weakness
Arthralgia or arthritis
Contractures
Constitutional signs or
symptoms
Fatigue
Weight loss
Fever
Cardiac system
Cardiac abnormalities on
EKG or echocardiogram
Palpitations
Gastrointestinal system
Dysphagia
Abdominal pain
Regurgitation
Constipation
Pulmonary system
Dysphonia
Interstitial lung disease
Cutaneous system
Periungual capillary changes
Raynaud’s phenomenon
Photosensitivity
Mechanic’s hands
Lipodystrophy

39 (100.0)
16 (44.4)
25 (64.1)
23 (60.5)
17 (45.9)†
7 (18.4)
27 (69.2)
16 (41.0)

9 (100.0)
7 (77.8)
6 (66.7)
5 (62.5)
8 (88.9)†
3 (33.3)
5 (55.6)
5 (55.6)

32 (82.1)
21 (53.8)
18 (47.4)

5 (55.6)
2 (22.2)
1 (11.1)

14 (36.8)

5 (62.5)

9 (23.1)

1 (11.1)

16 (41.0)
12 (30.8)
6 (15.4)
3 (7.7)

1 (11.1)
3 (33.3)
1 (11.1)
1 (11.1)

9 (23.7)
7 (17.9)

1 (11.1)
1 (12.5)

12 (30.8)
11 (28.2)
2 (5.1)
1 (2.6)
0 (0.0)

0 (0.0)
1 (11.1)
1 (11.1)
0 (0.0)
1 (11.1)

* Values are the number (percentage). Percentages may not reﬂect
the number divided by the total number of subjects when data are
missing. PM ⫽ polymyositis; EKG ⫽ electrocardiogram.
† P ⫽ 0.027.

ans and interquartile ranges (IQRs), and P values for differences between patient groups were obtained by the
Mann-Whitney rank sum test. Fisher’s exact test was used
to compare proportions between groups. A P value of 0.05
or less was considered signiﬁcant. Because the analyses
were exploratory, correction for multiple comparisons was
not performed. Random forests classiﬁcation analysis was
performed to further evaluate signiﬁcant univariate differences between patients with juvenile PM and those with
dystrophies (15). The random forests classiﬁcation algorithm was performed using the statistical language R
(version 2.13.1, 2011; http://stat-www.berkeley.edu/users/
breiman/RandomForests/). Due to the difference in sample
size between the groups, the data were resampled to ensure balance, using the method of undersampling from the
larger group (15). The statistical model had 500 forests and
20,000 trees per run, and the mean decrease in accuracy
(MDA) was calculated. The mean out-of-bag error rate for
the model was 6.7%. Backward stepwise logistic regres-
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Table 3. Laboratory test abnormalities in patients with juvenile PM
versus muscular dystrophy*

Autoantibodies
Antinuclear antibodies
Any myositis autoantibody
Myositis-speciﬁc autoantibodies
Anti–Jo-1
Anti-SRP
Myositis-associated autoantibodies‡
Anti–U1 RNP
Anti-Ro
Anti-La
Anti–PM-Scl
Anti–U2 RNP, anti–TMG cap, anti-Sm (1 each)
Magnetic resonance imaging
Muscle edema
Myofasciitis
Subcutaneous edema
Muscle atrophy
Fatty replacement of muscles
Electromyography
Increased insertional and spontaneous activity
in the form of ﬁbrillation potentials
Short duration, small amplitude polyphasic
motor unit action potentials
Complex repetitive discharge
Positive sharp waves

Juvenile PM
(n ⴝ 39)

Dystrophy
(n ⴝ 9)

24 (61.5)
21 (53.8)†

3 (33.3)
0 (0.0)†

4 (10.3)
6 (15.4)

0 (0.0)
0 (0.0)

7 (17.9)
4 (10.3)
2 (5.1)
2 (5.1)
3 (7.7)

0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)

16 (76.2)
11 (52.4)
4 (19.0)
4 (19.0)§
5 (23.8)

2 (33.3)
1 (16.7)
1 (16.7)
5 (83.3)§
4 (66.7)

20 (87.0)

5 (55.6)

17 (73.9)

7 (77.8)

16 (69.6)¶
4 (60.9)

2 (22.2)¶
3 (33.3)

* Values are the number (percentage). Percentages may not reﬂect the number divided by the total number
of subjects when data are missing. One patient with anti–Jo-1 also had anti-Ro and anti-La autoantibodies
and another Jo-1–positive patient also had anti–U1 RNP and anti-Sm autoantibodies. Of the myositisassociated autoantibodies, 1 patient had both anti-Ro and anti-La autoantibodies, 1 patient had anti–U1
RNP and anti-Sm autoantibodies, and 1 patient had anti–U1 RNP, anti–U2 RNP, anti-Ro, anti-La, and
anti–TMG cap autoantibodies. PM ⫽ polymyositis; anti-SRP ⫽ anti–signal recognition particle; antiTMG ⫽ anti-trimethylguanosine.
† P ⫽ 0.003.
‡ Some patients had ⬎1 myositis-associated autoantibody.
§ P ⫽ 0.008.
¶ P ⫽ 0.02.

sion analysis was also performed with signiﬁcant variables
from the univariable analysis using Stata, version 12.1.
Variables signiﬁcant in the univariable analysis with missing data could not be examined in the random forests
analysis or by logistic regression modeling. Sensitivity,
speciﬁcity, and positive and negative predictive values for
juvenile PM versus dystrophy were calculated using the
variables in the ﬁnal logistic regression model using the
prevalence of juvenile PM in the full sample (0.8).

RESULTS
Patients with muscular dystrophy had a longer delay to
diagnosis (median 12.0 months) than patients with juvenile PM (median 4.0 months) (Table 1). There was no
difference in the age at diagnosis or racial distribution
between patients with juvenile PM and muscular dystrophy. The female:male ratio was 3.3:1 in the juvenile PM
group compared to 1.3:1 in the dystrophy group. Patients

with dystrophies tended to have a more insidious disease
onset (78% versus 38% in juvenile PM patients; P ⫽ 0.06)
(Table 1). There was no difference in the frequency of a
family history of autoimmune disease. Hospitalization was
more frequent in patients with juvenile PM compared to
patients with dystrophies (74% versus 22%; P ⫽ 0.007).
The number of patients reporting use of a wheelchair was
similar. Mortality did not differ between the 2 groups.
Regarding the clinical features of juvenile PM and
muscular dystrophy (Table 2), muscle atrophy was more
frequent in patients with muscular dystrophy (89%)
compared to those with juvenile PM (46%; P ⫽ 0.027).
Fever occurred more often in juvenile PM patients who
had overlap myositis (62%) than in patients with muscular dystrophy (11%; P ⫽ 0.05), but was not signiﬁcantly different between the total juvenile PM group (47%)
compared to those with dystrophies. The other reported
clinical features did not differ between the 2 groups of
patients.

Features Distinguishing Juvenile Polymyositis and Dystrophies
The frequency of abnormal values and serum muscle
enzyme levels, including creatine kinase, aldolase, lactate
dehydrogenase, and transaminases, and the ratio of aspartate aminotransferase to alanine aminotransferase levels
did not differ between juvenile PM and muscular dystrophy patients. For example, the median creatine kinase
level was 7,439 units/liter (IQR 224 –53,896) in juvenile
PM patients and 13,541 units/liter (IQR 551–56,941) in
patients with dystrophies (P ⫽ 0.5). The median aldolase
level was 27 units/liter (IQR 3–217) in juvenile PM patients and 59 units/liter (IQR 8 –1,756) in patients with
dystrophies (P ⫽ 0.27).
Twenty-four patients (62%) in the juvenile PM group
had a positive antinuclear antibody compared with 3 patients (33%) in the dystrophy group (Table 3). Patients
with juvenile PM were more frequently positive for one of
the myositis autoantibodies (54%), but none of the dystrophy patients had a myositis autoantibody (P ⫽ 0.003)
(Table 3). Muscle atrophy on MRI of the thighs was more
frequent in patients with muscular dystrophy compared to
patients with juvenile PM (83% versus 19%; P ⫽ 0.008)
(Table 3). The frequency of other MRI features, including
muscle edema, myofasciitis, subcutaneous edema, and
fatty replacement of the muscles, did not differ between
juvenile PM and dystrophy patients. Complex repetitive
discharges were more often reported in the EMGs of juvenile PM patients compared with dystrophy patients (70%
versus 22%; P ⫽ 0.02). The other EMG features (increased
insertional and spontaneous activity in the form of ﬁbrillation potentials, small amplitude polyphasic motor unit
action potentials, and positive sharp waves) did not differ
between the groups.
Comparing the muscle biopsy characteristics of juvenile PM and muscular dystrophy patients (Table 4), patients with dystrophies more often had diffuse variation
of myoﬁber size (100% versus 53%; P ⫽ 0.008), as well
as ﬁber hypertrophy (44% versus 8%; P ⫽ 0.018) and
myoﬁber ﬁbrosis (56% versus 10%; P ⫽ 0.007). Other
histopathologic features on muscle biopsy, including inﬂammatory changes, did not differ between the 2 groups
(Table 4).
In terms of therapy, 1 muscular dystrophy patient was
treated with prednisone alone and 8 were treated with
prednisone in combination with other immunosuppressive agents, whereas 9 juvenile PM patients were treated
with prednisone alone and 30 were treated with a combination of prednisone and other immunosuppressive
agents. Methotrexate alone was the most frequently used
immunosuppressive agent in both juvenile PM patients
(40%) and muscular dystrophy patients (56%). The absence of a clinical response to treatment was more frequent in patients with dystrophies compared to those
with juvenile PM (33% versus 0.0%; P ⫽ 0.005). There
were no differences in the frequency of partial clinical
responses to treatment. None of the dystrophy patients
had a complete response to therapy, whereas 43.6% of
patients with juvenile PM had a complete clinical response (P ⫽ 0.018).
Random forests analysis was used to examine the 9
distinguishing features between juvenile PM and dystro-

1973

Table 4. Muscle biopsy features of patients with
juvenile PM versus muscular dystrophy*
Juvenile PM Dystrophy
(n ⴝ 39)
(n ⴝ 9)
Endomysial inﬁltration of
mononuclear cells surrounding
but not invading myoﬁbers
Non-necrotic myoﬁbers surrounded
and invaded by mononuclear
cells
Perimysial and/or perivascular
inﬁltration of mononuclear cells
Phagocytosis
Presence of macrophages/
histiocytes
Myofasciitis
Myoﬁber degeneration/regeneration
Necrosis of type I and type II
myoﬁbers
Many necrotic muscle ﬁbers as
the predominant feature;
inﬂammatory cells are sparse
Diffuse variation of myoﬁber size
Rounded ﬁber at the edge of the
fascicle
Fiber hypertrophy
Hypercontracted ﬁbers
Perifascicular atrophy
Myoﬁber ﬁbrosis
Fiber fatty replacement

23 (60.5)

5 (55.6)

3 (7.9)

0 (0.0)

26 (68.4)

3 (33.3)

9 (23.7)
13 (34.2)

2 (22.2)
2 (22.2)

2 (5.3)
25 (65.8)
15 (39.5)

1 (11.1)
7 (77.8)
2 (22.2)

3 (7.9)

1 (11.1)

20 (52.6)†
6 (15.8)

9 (100.0)†
1 (11.1)

3 (7.9)‡
2 (5.3)
12 (31.6)
4 (10.5)§
1 (2.6)

4 (44.4)‡
1 (11.1)
1 (11.1)
5 (55.6)§
2 (22.2)

* Values are the number (percentage). Percentages may not reﬂect
the number divided by the total number of subjects when data are
missing. PM ⫽ polymyositis.
† P ⫽ 0.008.
‡ P ⫽ 0.018.
§ P ⫽ 0.007.

phies that were signiﬁcant on univariate analysis and for
which no data were missing; 3 juvenile PM patients were
excluded from this analysis due to missing variables. Random forests analysis revealed that myositis autoantibodies were best for discriminating juvenile PM from dystrophies (average MDA score 100.0), followed by clinical
muscle atrophy (MDA 45.0), diffuse variation in myoﬁber
size (MDA 35.9), and total response to immunosuppressive therapy (MDA 32.0).
Multivariate logistic regression analysis revealed that
more frequent hospitalization (odds ratio [OR] 32.8, 95%
conﬁdence interval [95% CI] 2.2– 478.5), less frequent
myoﬁber ﬁbrosis on biopsy (OR 0.06, 95% CI 0.004 – 0.77),
and less frequent muscle atrophy on examination (OR
0.067, 95% CI 0.033–1.21) were signiﬁcant predictors of
juvenile PM compared to dystrophy. Because none of the
dystrophy patients had a myositis autoantibody, a point
estimate could not be obtained for this variable. The ﬁnal multivariable model using hospitalization, myoﬁber
ﬁbrosis on biopsy, and clinical muscle atrophy provided
a sensitivity of 91.4% and a speciﬁcity of 77.8% for detecting juvenile PM versus dystrophy, with a positive pre-
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dictive value of 94.1% and a negative predictive value of
70.0%.

DISCUSSION
Distinguishing between juvenile PM and muscular dystrophies can be clinically challenging, since both conditions
are characterized by the presence of chronic muscle weakness and inﬂammation and share a number of clinical
features. As demonstrated here, 9 muscular dystrophy patients were initially misdiagnosed as having juvenile PM
and were correctly diagnosed only after further careful
evaluation, including eventual pathologic or genetic testing. We systematically examined many different characteristics of patients with juvenile PM or deﬁned muscular
dystrophies, including demographics, clinical ﬁndings,
laboratory results, outcomes, and treatment responses, to
identify distinguishing features of these conditions.
Compared to patients with juvenile PM, patients with
dystrophies had more frequent muscle atrophy clinically
and on MRI, did not have myositis autoantibodies, and
had certain myopathic muscle biopsy ﬁndings more frequently, including the presence of diffuse variation of
myoﬁber size, ﬁber hypertrophy, and myoﬁber ﬁbrosis.
Patients with juvenile PM, in contrast, were more often
hospitalized and more frequently had a clinical response
to treatment with prednisone and/or other immunosuppressive agents.
Many of the clinical and demographic features and
the serum muscle enzyme levels were indistinguishable
between juvenile PM and dystrophy patients. This suggests that further investigation and careful evaluation are
needed for children presenting with muscle weakness and
enzyme changes without the characteristic skin rashes of
juvenile dermatomyositis. The level of creatine kinase elevation (16) or the presence of muscle edema on MRI
(17,18) has been noted to be similar in adult patients with
PM and dystrophies, as we also observed in this pediatric
study. We did not have information on other inﬂammatory
markers, such as neopterin or von Willebrand factor antigen level (1), and differences in these variables between
patients with juvenile PM and dystrophies. Endomysial
lymphocytic inﬁltrates, considered to be a hallmark of PM,
are frequently present in certain dystrophies (19,20). We
did not observe differences in the inﬂammatory features of
the muscle biopsy samples of juvenile PM and dystrophy
patients.
Some of the features we found that differentiate juvenile
PM from muscular dystrophies have been noted individually by others in distinguishing adult PM from dystrophies, based on case reports and limited clinical experience, or based on examination of a single laboratory test,
rather than from a systematic investigation such as this
one. Prior distinctions between PM and dystrophies have
included a slower rate of progression and lack of response
to immunosuppressive therapy in dystrophy patients
(17,19,20), as well as a stronger family history of autoimmune disease in patients with IIMs (21). The higher
frequency of a positive antinuclear antibody test and the
presence of myositis autoantibodies in patients with PM
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and not in patients with dystrophies also have been observed previously (17,22,23) and were conﬁrmed here.
Patients with dystrophies often have weakness in other
muscle groups or additional clinical manifestations, such
as muscle hypertrophy, scapular winging, spinal rigidity,
and macroglossia, which are absent in patients with PM,
and they may have a family history of muscle disease
(24,25). However, those features were not part of our questionnaire and therefore could not be assessed.
The differences in the biopsy features that we observed
included the myopathic features, which were more frequent in the dystrophy group, including myoﬁber size
variation, ﬁber hypertrophy, and hypercontracted ﬁbers.
In a previous study in which 13 patients were misdiagnosed with juvenile PM and had undetected dystrophies,
the distinguishing biopsy features in patients with dystrophies included subsarcolemmal blebbing, isolated ﬁber
degeneration without accompanying inﬂammation, and a
perimysial inﬁltrate consisting of macrophages (6). We did
not ﬁnd differences in these latter biopsy features in this
study and did not examine subsarcolemmal blebbing. The
presence of diffuse class I major histocompatibility complex (class I MHC) antigen expression on the sarcolemma
of muscle ﬁbers is an important feature for distinguishing
inﬂammatory from noninﬂammatory myopathies (26 –28).
However, class I MHC antigen staining of myoﬁbers has
also been described in some forms of dystrophies, including dysferlinopathies and Duchenne’s muscular dystrophy
(29). We did not have access to class I MHC staining. The
common biopsy features of juvenile PM included not only
endomysial inﬂammation, but also the frequent presence
of perimysial and/or perivascular inﬂammation, myoﬁber
degeneration/regeneration, and even perifascicular atrophy, which are thought to be characteristic of dermatomyositis (30).
A strength of our study is the simultaneous examination of many features of similar, and often misdiagnosed,
muscle diseases to determine which are most strongly
associated with juvenile PM versus the dystrophies. However, because not all patients had an MRI or EMG examination, we were unable to analyze these particular test
results in multivariable modeling. We were also unable to
examine differences in the time to treatment responses
because of an absence of detailed response to therapy data
over time. Due to the rarity of these conditions, the small
sample sizes also limited the power of the multivariable
modeling and the overall study. The population of patients
studied also may have potential selection bias, in that the
majority of patients were submitted by rheumatologists.
Given the multiple comparisons made, the ﬁndings would
be susceptible to Type I error, although this is preferred
to avoid rejecting the null hypothesis too readily in exploratory analyses (31). Future studies are needed to conﬁrm
the robustness of these data when applied to a larger
population.
In conclusion, muscular dystrophy can present clinically very similarly to juvenile IIM, particularly juvenile
PM. Speciﬁc clinical ﬁndings, responses to immunosuppressive therapies, and laboratory test results help distinguish muscular dystrophy and juvenile PM.
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Ramesh Pappu, Maria D. Perez, Karin S. Peterson, Paul H. Plotz,
Marilynn G. Punaro, Charles D. Radis, Linda I. Ray, Robert M.
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